Detalles de la búsqueda
1.
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
Eur J Cancer
; 62: 62-75, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27208905
Resultados
1 -
1
de 1
1
Próxima >
>>